Discover.
Launch.
Build.
Transform.

Synnovation Therapeutics

Synnovation Therapeutics is a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets.

Synnovation Therapeutics

bluebird bio

The FDA announced the approval of bluebird’s Lyfgenia for the treatment of sickle cell disease. Lyfgenia represents one of the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. SCD is a rare, debilitating and life-threatening blood disorder with significant unmet need. Gene therapy holds the promise of delivering more targeted and effective treatments, especially for individuals with rare diseases where the current treatment options are limited.

ARTBIO

ARTBIO is redefining cancer care by developing a new class of alpha radioligand therapies (ART) and building the ecosystem that maximizes their potential

ARTBIO

Sage Therapeutics

Sage and Biogen announced FDA approval for ZURZUVAE™ (zuranolone) in the treatment of postpartum depression (PPD). ZURZUVAE™ is a 14-day, rapid-acting, once-daily, oral treatment in adults with PPD. Mental health conditions are the leading cause of maternal mortality with PPD among the most common complications during and after pregnancy and ZURZUVAE™ is a fast-acting new option that can address this highly unmet medical need.

Rapport Therapeutics

Rapport is dedicated to the discovery and development of precision medicines for neurological disorders.

Rapport Therapeutics

CARGO Therapeutics

CARGO Therapeutics is outsmarting cancer to deliver more cures.

CARGO Therapeutics

bluebird bio

bluebird bio received FDA accelerated approval for SKYSONA® (elivaldogene autotemcel) gene therapy for early, active cerebral adrenoleukodystrophy (CALD). SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys with this devastating and fatal neurodegenerative disease.

bluebird bio

Living our core values.

One of Third Rock’s founding core values is to do the right thing. We believe diversity fuels innovation and are committed to fostering inclusion and diversity in all we do. That's why we are proud to be one of the founding members of the Bioscience & Investor Inclusion Group (BIIG), a coalition created to address diversity, equity and inclusion in the life sciences sector.

Learn more

Terremoto Biosciences

Terremoto is harnessing covalent chemistry to discover and develop small molecule medicines.

Terremoto Biosciences

MyoKardia

Bristol Myers Squibb (BMS) received approval from the U.S. FDA for Camzyos® (mavacamten). Camzyos, the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive hypertrophic cardiomyopathy, was originally developed by Third Rock portfolio company, MyoKardia, which was acquired by BMS in 2020.

bluebird bio

bluebird bio and Bristol Myers Squibb received approval from the U.S. Food and Drug Administration (FDA) for Abecma® (idecabtagene vicleucel) as the first CAR T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma.

bluebird bio
16

Years

64

Portfolio Companies

21

Marketed Products

1

Priority: Patients